Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.
Current Value
$110.321 Year Return
Current Value
$110.321 Year Return
Market Cap
$13.38B
P/E Ratio
44.66
1Y Stock Return
23.61%
1Y Revenue Growth
-2.66%
Dividend Yield
0.26%
Price to Book
1.7
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TMO | 61.43% | $194.74B | +5.54% | 0.30% |
A | 61.09% | $36.11B | +1.43% | 0.75% |
TECH | 59.45% | $10.55B | +4.49% | 0.48% |
BIO | 55.94% | $8.98B | +4.73% | 0.00% |
ILMN | 55.14% | $21.41B | +44.38% | 0.00% |
MTD | 54.49% | $24.49B | +6.92% | 0.00% |
ON | 54.45% | $28.38B | -2.54% | 0.00% |
WAT | 54.13% | $20.47B | +25.51% | 0.00% |
SWK | 52.67% | $13.31B | -3.30% | 3.75% |
AZTA | 52.29% | $2.00B | -28.24% | 0.00% |
WSFS | 51.51% | $3.39B | +48.16% | 1.02% |
DHR | 51.47% | $166.73B | +5.96% | 0.46% |
CE | 51.41% | $7.89B | -44.64% | 3.89% |
SXT | 51.27% | $3.24B | +33.26% | 2.15% |
PDM | 51.22% | $1.17B | +53.51% | 5.34% |
BRKR | 51.04% | $7.31B | -25.31% | 0.39% |
KWR | 51.01% | $2.91B | -5.30% | 1.14% |
STEL | 50.85% | $1.58B | +26.76% | 1.77% |
SFBS | 50.74% | $5.11B | +85.58% | 1.29% |
JLL | 50.67% | $12.26B | +68.32% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EG | 0.02% | $15.92B | -8.98% | 2.02% |
GAN | 0.06% | $83.39M | +21.19% | 0.00% |
OXBR | 0.06% | $19.05M | +178.18% | 0.00% |
MMYT | 0.08% | $11.31B | +142.64% | 0.00% |
RLMD | 0.11% | $89.92M | +1.36% | 0.00% |
TGS | 0.15% | $1.97B | +116.04% | 0.00% |
CNK | -0.15% | $4.09B | +138.59% | 0.00% |
NEUE | -0.16% | $40.93M | -34.13% | 0.00% |
ZCMD | 0.19% | $2.80M | -88.67% | 0.00% |
YPF | 0.22% | $13.98B | +139.72% | 0.00% |
LEU | -0.22% | $1.12B | +33.82% | 0.00% |
OCX | 0.24% | $42.93M | -36.09% | 0.00% |
SRRK | 0.26% | $2.61B | +134.91% | 0.00% |
PRPH | 0.28% | $18.14M | -82.61% | 0.00% |
UNM | -0.36% | $13.16B | +69.20% | 2.16% |
TMUS | 0.37% | $270.63B | +56.92% | 0.83% |
QTTB | 0.38% | $354.34M | +188.64% | 0.00% |
FTNT | -0.41% | $69.59B | +72.67% | 0.00% |
KSPI | -0.42% | $20.86B | +18.06% | 3.37% |
NTIC | 0.55% | $132.27M | +24.98% | 2.02% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PGR | -17.40% | $149.10B | +57.29% | 0.45% |
HUSA | -17.16% | $16.69M | -11.56% | 0.00% |
MCK | -15.36% | $78.15B | +35.51% | 0.42% |
PULM | -14.67% | $19.83M | +202.98% | 0.00% |
NNE | -13.79% | $833.66M | +531.50% | 0.00% |
ACGL | -12.26% | $36.00B | +16.84% | 0.00% |
TCTM | -10.85% | $8.10M | -42.99% | 0.00% |
CBOE | -7.85% | $21.46B | +15.84% | 1.11% |
TEO | -7.66% | $1.69B | +87.97% | 0.00% |
LPLA | -7.30% | $23.55B | +38.13% | 0.38% |
WRB | -6.96% | $22.94B | +29.98% | 0.69% |
RNR | -6.52% | $13.74B | +23.09% | 0.58% |
ABEO | -6.34% | $256.04M | +41.25% | 0.00% |
VIST | -6.19% | $4.75B | +67.10% | 0.00% |
AJG | -5.29% | $64.17B | +17.51% | 0.80% |
XPO | -4.98% | $16.97B | +63.79% | 0.00% |
MNR | -4.82% | $1.66B | -10.71% | 15.90% |
COR | -4.43% | $47.48B | +21.20% | 0.86% |
LPTH | -4.11% | $62.27M | +33.05% | 0.00% |
VIRT | -3.46% | $3.17B | +110.38% | 2.60% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPH | 66.23% | $885.96M | 0.4% |
MOAT | 64.08% | $15.73B | 0.46% |
FBT | 62.85% | $1.11B | 0.56% |
FXH | 61.60% | $1.15B | 0.62% |
IBB | 61.48% | $6.66B | 0.45% |
EZM | 60.23% | $823.84M | 0.38% |
VONV | 60.14% | $10.03B | 0.08% |
IJS | 59.93% | $7.37B | 0.18% |
BBH | 59.83% | $397.87M | 0.35% |
FSMD | 59.80% | $583.89M | 0.15% |
VIOV | 59.70% | $1.44B | 0.15% |
GNOM | 59.70% | $70.59M | 0.5% |
SLYV | 59.58% | $4.16B | 0.15% |
SMOT | 59.50% | $374.04M | 0.49% |
SMDV | 59.34% | $754.57M | 0.4% |
IJR | 59.24% | $90.05B | 0.06% |
SPSM | 59.16% | $12.72B | 0.03% |
DON | 59.10% | $3.90B | 0.38% |
IWS | 59.08% | $13.85B | 0.23% |
REGL | 59.05% | $1.65B | 0.4% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BOXX | 0.02% | $4.43B | 0.1949% |
DBA | -0.13% | $755.88M | 0.93% |
HIGH | -0.49% | $302.78M | 0.51% |
SOYB | 0.69% | $27.32M | 0.22% |
DBMF | 1.50% | $1.02B | 0.85% |
HDRO | -1.64% | $164.26M | 0.3% |
FBY | 1.86% | $127.69M | 0.99% |
CORN | 2.25% | $61.12M | 0.2% |
WEAT | 2.40% | $120.27M | 0.28% |
MINT | 2.65% | $11.62B | 0.35% |
CLOI | 2.80% | $715.40M | 0.4% |
CSHI | -2.94% | $482.85M | 0.38% |
FMF | 3.33% | $244.61M | 0.95% |
TBIL | -3.33% | $4.38B | 0.15% |
JBBB | 4.02% | $1.26B | 0.49% |
XBIL | 4.21% | $637.70M | 0.15% |
KRBN | 4.72% | $242.47M | 0.85% |
DBE | 4.77% | $50.13M | 0.77% |
GBIL | 5.11% | $5.60B | 0.12% |
SGOV | 5.36% | $27.53B | 0.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -46.36% | $388.04M | 1.43% |
USDU | -34.71% | $201.97M | 0.5% |
UUP | -32.90% | $309.25M | 0.77% |
VIXY | -28.65% | $195.31M | 0.85% |
EQLS | -21.41% | $76.08M | 1% |
CTA | -16.87% | $350.27M | 0.78% |
AGZD | -10.81% | $142.76M | 0.23% |
BILZ | -10.63% | $563.02M | 0.14% |
KMLM | -10.57% | $353.87M | 0.9% |
TAIL | -10.31% | $67.98M | 0.59% |
KCCA | -7.92% | $220.51M | 0.87% |
TBIL | -3.33% | $4.38B | 0.15% |
CSHI | -2.94% | $482.85M | 0.38% |
HDRO | -1.64% | $164.26M | 0.3% |
HIGH | -0.49% | $302.78M | 0.51% |
DBA | -0.13% | $755.88M | 0.93% |
BOXX | 0.02% | $4.43B | 0.1949% |
SOYB | 0.69% | $27.32M | 0.22% |
DBMF | 1.50% | $1.02B | 0.85% |
FBY | 1.86% | $127.69M | 0.99% |
Yahoo
WALTHAM, Mass., November 20, 2024--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties’ long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England’s renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare f
Yahoo
SAN DIEGO, November 19, 2024--Scale Biosciences and Revvity’s BioLegend launch first-of-its-kind solution for high parameter protein profiling of single cells.
Yahoo
WALTHAM, Mass., November 19, 2024--Revvity, Inc. (NYSE: RVTY), will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL.
Yahoo
WALTHAM, Mass., November 18, 2024--Revvity, Inc. (NYSE: RVTY), today announced it will host an Investor Day on Thursday, November 21, 2024 at 9:00 a.m. PT which will feature presentations by members of Revvity’s senior management team on the Company’s key business initiatives, operational achievements and future financial outlook.
MarketWatch
Revvity Inc. stock underperforms Friday when compared to competitors
MarketWatch
Revvity Inc. stock underperforms Thursday when compared to competitors
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.